1 Reason to Buy NVO

There's more to the company's leading product than meets the eye. It's one thing for a pharmaceutical company to have a blockbuster drug in its portfolio. It's quite another if such a product can be successfully extended to win approvals for other indications. This is one huge reason to believe in the future of Novo Nordisk (NVO 1.82%), the Danish company behind the immensely popular Wegovy obesity treatment. Last week the company earned a new feather in its cap with the product, and it feels as if it has f ...